Enanta Pharmaceuticals Inc. (ENTA)

62.61
0.57 0.92
NASDAQ : Health Technology
Prev Close 62.04
Open 62.52
Day Low/High 61.65 / 62.89
52 Wk Low/High 57.15 / 106.80
Volume 74.97K
Avg Volume 191.70K
Exchange NASDAQ
Shares Outstanding 19.68M
Market Cap 1.21B
EPS 3.70
P/E Ratio 20.13
Div & Yield N.A. (N.A)

Latest News

Enanta Pharmaceuticals To Present At The 2019 Wolfe Research Healthcare Conference

Enanta Pharmaceuticals To Present At The 2019 Wolfe Research Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

New Data From Enanta's Phase 2a Human Challenge Study Of EDP-938 For RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) In Total Symptom Score, Mucus Weight And RSV Viral Load As Measured By RT-PCR Assay And By Plaque Assay

New Data From Enanta's Phase 2a Human Challenge Study Of EDP-938 For RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) In Total Symptom Score, Mucus Weight And RSV Viral Load As Measured By RT-PCR Assay And By Plaque Assay

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new data from its Phase 2a Human Challenge Study...

Enanta Announces Positive Results Of ARGON-1 Study Of Its Lead FXR Agonist, EDP-305, For The Treatment Of NASH

Enanta Announces Positive Results Of ARGON-1 Study Of Its Lead FXR Agonist, EDP-305, For The Treatment Of NASH

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results from its ARGON-1 Phase 2a study of...

New Data From Enanta's Phase 2a Human Challenge Study Of EDP-938 For RSV To Be Presented At IDWeek&trade; 2019

New Data From Enanta's Phase 2a Human Challenge Study Of EDP-938 For RSV To Be Presented At IDWeek™ 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new data from its Phase 2a Human Challenge Study...

Enanta Pharmaceuticals To Present At The Baird 2019 Global Healthcare Conference

Enanta Pharmaceuticals To Present At The Baird 2019 Global Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2019

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended...

Enanta's HCV Collaboration Partner AbbVie Receives Approval By The European Commission For MAVIRET&trade; (glecaprevir/pibrentasvir) To Shorten Treatment Duration To Eight Weeks For Treatment-Na&iuml;ve HCV Patients With Compensated Cirrhosis

Enanta's HCV Collaboration Partner AbbVie Receives Approval By The European Commission For MAVIRET™ (glecaprevir/pibrentasvir) To Shorten Treatment Duration To Eight Weeks For Treatment-Naïve HCV Patients With Compensated Cirrhosis

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European Commission has granted marketing...

Enanta Pharmaceuticals To Host Conference Call On August 6 At 4:30 Pm ET To Discuss Its Financial Results For Its Fiscal Third Quarter Ended June 30, 2019

Enanta Pharmaceuticals To Host Conference Call On August 6 At 4:30 Pm ET To Discuss Its Financial Results For Its Fiscal Third Quarter Ended June 30, 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its...

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-514, Its Lead Core Inhibitor For The Treatment Of Hepatitis B Virus (HBV)

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-514, Its Lead Core Inhibitor For The Treatment Of Hepatitis B Virus (HBV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has initiated part 1 of a Phase 1a/b clinical...

Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved Its Primary And Secondary Endpoints In Its Phase 2a Human Challenge Study In Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved Its Primary And Secondary Endpoints In Its Phase 2a Human Challenge Study In Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results that demonstrated that EDP-938...

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals To Present At Upcoming Investor Conference

Enanta Pharmaceuticals To Present At Upcoming Investor Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2019

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended...

Enanta Pharmaceuticals To Host Conference Call On May 7th At 4:30 Pm ET To Discuss Its Financial Results For Its Fiscal Second Quarter Ended March 31, 2019

Enanta Pharmaceuticals To Host Conference Call On May 7th At 4:30 Pm ET To Discuss Its Financial Results For Its Fiscal Second Quarter Ended March 31, 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its...

Enanta Pharmaceuticals Enters Oversold Territory (ENTA)

Enanta Pharmaceuticals Enters Oversold Territory (ENTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Enanta Pharmaceuticals Presents New Preclinical Data On Compounds Targeting Hepatitis B Virus And Non-Alcoholic Steatohepatitis At The International Liver Congress&trade; 2019

Enanta Pharmaceuticals Presents New Preclinical Data On Compounds Targeting Hepatitis B Virus And Non-Alcoholic Steatohepatitis At The International Liver Congress™ 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that new preclinical data from Enanta's wholly-owned...

Enanta Pharmaceuticals Reaches Analyst Target Price

Enanta Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Enanta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $95.50, changing hands for $96.30/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Enanta Pharmaceuticals Announces Data Presentations At The International Liver Congress&trade; 2019

Enanta Pharmaceuticals Announces Data Presentations At The International Liver Congress™ 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data from Enanta's wholly-owned...

Enanta Pharmaceuticals Completes Enrollment In Two Ongoing Phase 2 Studies

Enanta Pharmaceuticals Completes Enrollment In Two Ongoing Phase 2 Studies

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced it has completed enrollment in two Phase 2 studies.

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

ENTA Crosses Above Average Analyst Target

ENTA Crosses Above Average Analyst Target

In recent trading, shares of Enanta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $95.50, changing hands for $95.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter And Three Months Ended December 31, 2018

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter And Three Months Ended December 31, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended...

Enanta Pharmaceuticals To Host Conference Call On February 6th At 4:30 Pm ET To Discuss Its Financial Results For Its Fiscal First Quarter Ended December 31, 2018

Enanta Pharmaceuticals To Host Conference Call On February 6th At 4:30 Pm ET To Discuss Its Financial Results For Its Fiscal First Quarter Ended December 31, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its...

Enanta Pharmaceuticals To Provide Updates On Its Research And Development Programs And Business Outlook For 2019 During The 37th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals To Provide Updates On Its Research And Development Programs And Business Outlook For 2019 During The 37th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals To Present At The 37th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals To Present At The 37th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALK, ARCO, BIOS, CRD.A, DCO, GNE, KEYW, LOGM, OUT, SIGA, TBBK, TGP, TPIC, XXII Downgrades: ADS, BYD, CCS, ENTA, HL, ICBK, MTW, XOMA Initiations: BPMP, PTGX Read on to get TheStreet Quant Ratings' detailed report:

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2018

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and...

Enanta Announces That AbbVie's MAVYRET&trade; (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates In Treatment-Na&iuml;ve Hepatitis C Patients With Compensated Cirrhosis

Enanta Announces That AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates In Treatment-Naïve Hepatitis C Patients With Compensated Cirrhosis

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the presentation of new data for AbbVie's...

TheStreet Quant Rating: C (Hold)